GlassScriptPhysician profile
Scott T Goodrich
NPI 1083748966
$3,728.34
in general payments reported to CMS, 2019-2025
25 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 76% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $127 · 2021: $337 · 2022: $353 · 2023: $247 · 2024: $439 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.43 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $1,138.46 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $381.53 | 2019-2025 | Enhertu, Lynparza |
| Seagen INC. | $324.30 | 2021-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $218.45 | 2022-2025 | Myrisk |
| Intuitive Surgical, INC. | $206.84 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.71 | 2019-2021 | |
| Abbvie INC. | $132.30 | 2024 | |
| Aspira Women'S Health INC | $125.00 | 2021 | |
| Genmab U.S., INC. | $125.00 | 2025 | Tivdak |
| Merck Sharp & Dohme LLC | $121.65 | 2019-2025 | Keytruda |
| Clovis Oncology, INC. | $108.73 | 2019-2020 | |
| Medical Device Business Services, INC. | $103.68 | 2025 | Vistaseal |
| Therapeuticsmd, INC. | $101.16 | 2019 | |
| Eisai INC. | $93.76 | 2022-2024 | |
| Daiichi Sankyo INC. | $92.80 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $90.34 | 2023 | Jemperli |
| Novartis Pharmaceuticals Corporation | $67.47 | 2025 | |
| Celgene Corporation | $32.60 | 2019 | |
| Tesaro, INC. | $18.71 | 2019 | |
| Acrotech Biopharma INC. | $18.42 | 2025 | Beleodaq |
| Kyowa Kirin, INC. | $18.01 | 2019 | |
| Immunogen, INC. | $16.83 | 2023 | Elahere |
| Genentech, INC. | $16.83 | 2021 | |
| Adaptive Biotechnologies Corporation | $14.17 | 2025 | Clonoseq |
| Amgen INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Goodrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.